Pipeline Milestones And Expanding Patient Pools Will Broaden Market Reach

Published
20 Mar 25
Updated
14 Aug 25
AnalystConsensusTarget's Fair Value
US$58.23
26.7% undervalued intrinsic discount
14 Aug
US$42.69
Loading
1Y
-9.0%
7D
-2.5%

Author's Valuation

US$58.2

26.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 0.26%

Shared on24 Apr 25

AnalystConsensusTarget has decreased shares outstanding growth rate from 0.1% to 0.0%.

Shared on17 Apr 25
Fair value Decreased 0.27%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 58.3x to 65.0x.

Shared on09 Apr 25
Fair value Decreased 1.80%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 0.20%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 1.39%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.